Sunday, February 7, 2016

Israeli company Regentis Biomaterials Raises $15M, round led by Chinese group Haisco

Israeli biomedical company Regentis Biomaterials announced today the closing their $15 million Series D funding round, led by Chinese pharmaceutical group Xizang Haisco Pharmaceutical Group Co. Ltd, a leading Chinese pharmaceutical group listed on the Shenzhen Stock Exchange (SHE:002653).

Also participated in the round existing investors: Medica Venture Partners, SCP Vitalife Partners, Italian asset manager Generali Investment, and the technology transfer company of the Technion, T3.

Regentis CEO and President is Dr. Alastair Clemow.

Regentis Biomaterials is developing hydrogels for tissue regeneration originally developed at the Technion University by Dr. Dror Seliktar. The company’s flagship product, GelrinC™, combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance. Currently the treatment is under clinical trials for the treatment of articular cartilage lesions.

Haisco Pharmaceutical Group, founded in 2000, is a publicly listed company focusing on marketing and sales of internally-developed therapeutic drugs. Haisco ranks third in size in China’s chemical pharmaceutical industry. The company’s products are sold to more than 3,000 hospitals throughout China with annual sales of over US$800 million.

Last year Haisco Group invested in two other Israeli medical device companies: $10 million were invested in October 2015 in Endospan and in July 2015 they invested $5 million in MST – Medical Surgery Technologies.

No comments:

Post a Comment